Ascus is pioneering Endomicrobial Ecology, an emerging science harnessing the natural diversity within an animal’s microbiome to improve animal health and performance. Integrating recent advancements in DNA and RNA sequencing methods with breakthrough methods of computational analysis, Endomicrobial Ecology fingerprints the specific microbes naturally residing within an animal’s gastrointestinal system and identifies how the microbes function and interact to influence health and performance. Based on this proprietary discovery platform, Ascus scientists have uncovered novel microbial strains, native to the animal, with a clear health and performance benefit. The goal of Ascus scientists is to use this enhanced understanding of an animal’s microbiome to develop products and services that improve the overall health and performance of animals.
The Study of Endomicrobial Ecology Leads to De Novo Discovery
Biology Focused Innovation
The insights resulting from de novo discovery research in Endomicrobial Ecology are building new tools to manage animal health and performance. According to Dr. William Weldon, chief operations officer at Ascus, Endomicrobial Ecology allows these new products to support the animal with solutions tailored to the animal’s natural biology. “There is no other technology or product that uses novel beneficial microbes derived from the animal’s own GI system to improve gastrointestinal health and performance,” said Weldon. “When used as the basis for feed supplements, the science of Endomicrobial Ecology is distinct from other additive technologies currently used in animal health and nutrition.”
Applying Insights in the Field
About Ascus, Inc.
Ascus Biosciences, based in San Diego, CA with commercial operations headquartered in Indianapolis, is focused on discovering, developing, and commercializing first-in-class endomicrobial products for the animal health and nutrition industries. Founded in 2015, Ascus is pioneering the emerging science of endomicrobial ecology to illuminate microbial communities within animals, and the role they play in overall health and performance. Ascus has a broad pipeline of all-natural, endomicrobial products in development across livestock and companion animals. Galaxis is their lead product and will launch in 2018 in select international dairy markets.